Rhythm rises after European Commission approves drug for rare form of obesity

Rhythm Pharmaceuticals

01/05/2026 16:17

** Shares of drugmaker Rhythm Pharmaceuticals RYTM.O rise 2.6% to $83.45

** Co says the European Commission has approved its drug to treat obesity and control hunger in adults and children aged four and older with acquired hypothalamic obesity, a rare disorder caused by injury or damage to the hypothalamus

** The decision makes the drug Imcivree the first approved treatment in Europe for the condition

** The treatment won U.S. approval in March

** RYTM says it expects commercial launches in Europe in 2027 after seeking country-by-country access

** Including session's moves, RYTM down 22.3% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))